Btk inhibitors have demonstrated considerable success in clinical trials, particularly in combating B cell malignancies [33,34] and in the treatment of autoimmune disorders such as lupus and inflammatory arthritis in animal models [[35], [36], [37]]. This evidence concerns the gene BTK and systemic lupus erythematosus.